BeOne Medicines (ONC) Short-Term Debt issuances (2017 - 2026)

BeOne Medicines (ONC) has 8 years of Short-Term Debt issuances data on file, last reported at $58.2 million in Q1 2026.

• Quarterly Short-Term Debt issuances fell 27.24% year-over-year to $58.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $211.9 million (down 73.72% YoY) and the FY2025 annual result came in at $233.7 million, down 73.09% from the prior year.
• Short-Term Debt issuances climbed to $58.2 million in Q1 2026 per ONC's latest filing, from $12.2 million in the prior quarter.
• Across five years, Short-Term Debt issuances topped out at $543.9 million in Q4 2024 and bottomed at $768000.0 in Q3 2023.
• The 5-year median for Short-Term Debt issuances is $118.9 million (2022), against an average of $152.5 million.
• Peak annual rise in Short-Term Debt issuances reached 820.31% in 2023, while the deepest fall reached 99.2% in 2023.
• Tracing ONC's Short-Term Debt issuances over 5 years: stood at $150.0 million in 2022, then surged by 232.61% to $498.9 million in 2023, then climbed by 9.01% to $543.9 million in 2024, then slumped by 97.77% to $12.2 million in 2025, then jumped by 378.85% to $58.2 million in 2026.
• Per Business Quant, the three latest ONC Short-Term Debt issuances figures stand at $58.2 million (Q1 2026), $12.2 million (Q4 2025), and $141.5 million (Q2 2025).

Peer Comparison